Trastuzumab-deruxtecan in HER2 positive advanced gastric or gastroesophageal junction cancer after previous treatment with trastuzumab

被引：3
作者：
Duval, Jeanne [1 ]
Zaanan, Aziz [2 ]
机构：
[1] Univ Paris Sorbonne, Hop St Antoine, Dept oncol digest, 184 Rue Faubourg St Antoine, F-75012 Paris, France
[2] Univ Paris Cite, Georges Pompidou European Hosp, Assistance publ Hop Paris, Dept Digest Oncol, 20 Rue Leblanc, F-75015 Paris, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 7-8期
关键词：
D O I：
10.1016/j.bulcan.2023.04.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：739 / 740
页数：2
相关论文
共 7 条
[1]   Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Feyereislova, Andrea ;
Chung, Hyun C. ;
Shen, Lin ;
Sawaki, Akira ;
Lordick, Florian ;
Ohtsu, Atsushi ;
Omuro, Yasushi ;
Satoh, Taroh ;
Aprile, Giuseppe ;
Kulikov, Evgeny ;
Hill, Julie ;
Lehle, Michaela ;
Ruschoff, Josef ;
Kang, Yoon-Koo .
LANCET, 2010, 376 (9742) :687-697
[2]  
Ku, 2022, EUR SOC MED ONCOL
[3]   Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives [J].
Palle, Juliette ;
Rochand, Adrien ;
Pernot, Simon ;
Gallois, Claire ;
Taieb, Julien ;
Zaanan, Aziz .
DRUGS, 2020, 80 (04) :401-415
[4]   Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer [J].
Shitara, Kohei ;
Bang, Yung-Jue ;
Iwasa, Satoru ;
Sugimoto, Naotoshi ;
Ryu, Min-Hee ;
Sakai, Daisuke ;
Chung, Hyun-Cheol ;
Kawakami, Hisato ;
Yabusaki, Hiroshi ;
Lee, Jeeyun ;
Saito, Kaku ;
Kawaguchi, Yoshinori ;
Kamio, Takahiro ;
Kojima, Akihito ;
Sugihara, Masahiro ;
Yamaguchi, Kensei .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25) :2419-2430
[5]   Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study [J].
Shitara, Kohei ;
Iwata, Hiroji ;
Takahashi, Shunji ;
Tamura, Kenji ;
Park, Haeseong ;
Modi, Shanu ;
Tsurutani, Junji ;
Kadowaki, Shigenon ;
Yamaguchi, Kensei ;
Iwasa, Satoru ;
Saito, Kaku ;
Fujisaki, Yoshihiko ;
Sugihara, Masahiro ;
Shahidi, Javad ;
Doi, Toshihiko .
LANCET ONCOLOGY, 2019, 20 (06) :827-836
[6]   Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Shitara, Kohei ;
Doi, Toshihiko ;
Dvorkin, Mikhail ;
Mansoor, Wasat ;
Arkenau, Hendrik-Tobias ;
Prokharau, Aliaksandr ;
Alsina, Maria ;
Ghidini, Michele ;
Faustino, Catia ;
Gorbunova, Vera ;
Zhavrid, Edvard ;
Nishikawa, Kazuhiro ;
Hosokawa, Ayumu ;
Yalcin, Suayib ;
Fujitani, Kazumasa ;
Beretta, Giordano D. ;
Van Cutsem, Eric ;
Winkler, Robert E. ;
Makris, Lukas ;
Ilson, David H. ;
Tabernero, Josep .
LANCET ONCOLOGY, 2018, 19 (11) :1437-1448
[7]   Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial [J].
Wilke, Hansjochen ;
Muro, Kei ;
Van Cutsem, Eric ;
Oh, Sang-Cheul ;
Bodoky, Gyoergy ;
Shimada, Yasuhiro ;
Hironaka, Shuichi ;
Sugimoto, Naotoshi ;
Lipatov, Oleg ;
Kim, Tae-You ;
Cunningham, David ;
Rougier, Philippe ;
Komatsu, Yoshito ;
Ajani, Jaffer ;
Emig, Michael ;
Carlesi, Roberto ;
Ferry, David ;
Chandrawansa, Kumari ;
Schwartz, Jonathan D. ;
Ohtsu, Atsushi .
LANCET ONCOLOGY, 2014, 15 (11) :1224-1235
1